Table 2 Primary and secondary efficacy outcomes
Baricitinib group (N = 139) | Placebo group (N = 136) | Adjusted Absolute difference (95% CI) | Adjusted OR (95% CI) | P-value* | |
|---|---|---|---|---|---|
Mortality | |||||
Number of deaths at day 61 | 21 | 21 | |||
Proportion (95% CI) at day 61 | 15.1 (9.6–22.2) | 15.4 (9.8–22.6) | − 0.1 (− 8.3–8.0) | 0.99 (0.50–1.95) | 0.9733 |
Number of deaths at day 28+ | 14 | 18 | |||
Proportion (95% CI) at day 28+ | 10.1 (5.6–16.3) | 13.2 (8.0–20.1) | − 2.9 (− 10.1–4.3) | 0.75 (0.35–1.59) | 0.4480 |
Disease progression | |||||
Number of progressions at day 28 | 25 | 27 | |||
Proportion (95% CI) at day 28 | 18.0 (12.0–25.4) | 19.9 (13.5–27.6) | − 1.2 (− 10.0–7.4) | 0.92 (0.49–1.72) | 0.7943 |
Baricitinib group (N = 139) | Placebo group (N = 136) | Unadjusted sHR or OR (95% CI) | Adjusted sHR or OR (95% CI) | p value* | |
|---|---|---|---|---|---|
Sustained recovery | |||||
Number of recoveries at day 91 | 107 | 106 | |||
Cumulative incidence at day 91% (95% CI) | 78.8 (72.6–85.4) | 79.1 (72.9–85.8) | 0.99 (0.76–1.28) | 0.98 (0.75–1.28) | 0.8604 |
Hospital discharge | |||||
Number of discharges at day 91 | 111 | 107 | |||
Cumulative incidence at day 91% (95% CI) | 83.8 (77.7–90.3) | 79.8 (73.1–87.1) | 1.14 (0.88–1.47) | 1.14 (0.87–1.48) | 0.3490 |
Ordinal scale at day 15 – n (%) | 0.94 (0.60–1.48) | 0.95 (0.60–1.50) | 0.8296 | ||
Mild (WHO score 1–3) | 81 (58.3) | 74 (54.4) | |||
Moderate (WHO score 4–5) | 15 (10.8) | 18 (13.2) | |||
Severe (WHO score 6) | 10 (7.2) | 8 (5.9) | |||
Critical (WHO score 7–9) | 24 (17.2) | 26 (19.1) | |||
Death (WHO score 10) | 25 (6.5) | 10 (7.4) | |||
Ordinal scale at day 29 – n (%) | 1.13 (0.69–1.84) | 1.14 (0.70–1.87) | 0.5986 | ||
Mild (WHO score 1–3) | 96 (69.0) | 89 (65.4) | |||
Moderate (WHO score 4–5) | 97 (7.9) | 14 (10.3) | |||
Severe (WHO score 6) | 3 (2.2) | 4 (3.0) | |||
Critical (WHO score 7–9) | 4 (10.8) | 11 (8.1) | |||
Death (WHO score 10) | 14 (10.1) | 18 (13.2) | |||